Novel 3D Brain Marker Predicts Surgical Success in Dementia-Causing Hydrocephalus

Normal pressure hydrocephalus (NPH) is a treatable cause of dementia that often goes undiagnosed, particularly in older adults. Characterized by an abnormal buildup of cerebrospinal fluid in the brain’s ventricles, NPH leads to symptoms such as gait disturbances, urinary incontinence, and cognitive decline. Whereas shunt surgery can significantly improve outcomes, not all patients benefit equally, making preoperative prediction of surgical success critical. A recent study has identified a novel three-dimensional brain imaging marker that may help clinicians better predict which patients are most likely to respond positively to shunting procedures.

Understanding Normal Pressure Hydrocephalus and Its Challenges

NPH primarily affects individuals over the age of 60 and is frequently mistaken for Alzheimer’s disease or Parkinson’s due to overlapping symptoms. Unlike other forms of dementia, yet, NPH can be reversed with surgical intervention—specifically, the implantation of a ventriculoperitoneal shunt to drain excess fluid. According to the Hydrocephalus Association, an estimated 700,000 Americans may have NPH, yet fewer than 20% receive an accurate diagnosis.

The variability in surgical outcomes remains a major hurdle. While some patients experience dramatic improvements in mobility and cognition within weeks of shunt placement, others show minimal change. This inconsistency has driven research into biomarkers that could identify ideal surgical candidates before invasive procedures are undertaken.

Breakthrough in 3D Brain Imaging: The EOD Index

Researchers from a multi-institutional team led by scientists at the Mayo Clinic and the University of California, San Francisco, have developed a novel quantitative metric called the Expansion Index (EOD) derived from three-dimensional analysis of brain MRI scans. The EOD index measures the disproportionate enlargement of specific ventricular regions relative to surrounding brain tissue, particularly highlighting disproportionate enlargement of the temporal horns of the lateral ventricles—a pattern increasingly associated with NPH.

In a study published in JAMA Neurology in March 2024, researchers analyzed preoperative 3D T1-weighted MRI scans from 112 patients diagnosed with idiopathic NPH who subsequently underwent shunt surgery. Using advanced image processing algorithms, they calculated the EOD index for each patient and correlated it with postoperative outcomes at six months, measured by standardized gait and cognitive assessments.

The results showed that patients with an EOD index above a certain threshold were 3.4 times more likely to achieve meaningful clinical improvement after shunting compared to those with lower values. The marker demonstrated a sensitivity of 82% and specificity of 79% in predicting surgical success, outperforming traditional two-dimensional ventricular ratio measurements such as the Evans index.

“What makes the EOD index powerful is its ability to capture subtle, three-dimensional shifts in ventricular morphology that are missed by conventional radiology readings,” said Dr. Laura Chen, lead author of the study and neuroradiologist at Mayo Clinic. “This isn’t just about how big the ventricles are—it’s about where the expansion is happening and how it relates to nearby brain structures.”

Why This Matters for Patients and Clinicians

For patients suspected of having NPH, accurate prediction of surgical benefit can prevent unnecessary procedures and reduce healthcare costs. Shunt implantation, while generally safe, carries risks including infection, hemorrhage, and shunt malfunction. Identifying those most likely to benefit ensures that resources are directed toward interventions with the highest likelihood of success.

the EOD index could help reduce diagnostic delays. Because its calculation relies on standard MRI sequences already used in neurological evaluations, it can be integrated into existing clinical workflows without requiring additional scans or specialized equipment.

Dr. Natalie Singh, MPH, emphasizes the broader implications: “Tools like the EOD index represent a shift toward precision neurology—using advanced imaging not just to detect disease, but to personalize treatment. For a condition like NPH, where timely intervention can restore independence, this kind of biomarker has real potential to change lives.”

Future Directions and Ongoing Research

The research team is now working to validate the EOD index in larger, more diverse populations, including patients with secondary NPH caused by prior hemorrhage or meningitis. Efforts are also underway to develop automated software tools that can calculate the EOD index directly from clinical MRI scans, potentially enabling real-time decision support at the point of care.

scientists are exploring whether similar 3D shape-based markers could predict outcomes in other forms of ventriculomegaly or neurodegenerative conditions involving cerebrospinal fluid dynamics, such as normal-pressure variants of hydrocephalus seen in traumatic brain injury or idiopathic intracranial hypertension.

Key Takeaways

• Normal pressure hydrocephalus is a reversible cause of dementia often missed in older adults.
• Shunt surgery can improve symptoms, but patient selection remains challenging due to variable outcomes.
• The newly identified Expansion Index (EOD), derived from 3D brain MRI analysis, measures disproportionate ventricular enlargement and predicts surgical success with high accuracy.
• Patients with elevated EOD scores are significantly more likely to experience meaningful improvement after shunting.
• The marker uses standard imaging protocols and could be integrated into routine neurological assessments.
• Ongoing research aims to validate the EOD index across broader populations and develop automated analysis tools.

Frequently Asked Questions

What is normal pressure hydrocephalus (NPH)?

NPH is a neurological disorder characterized by an abnormal accumulation of cerebrospinal fluid in the brain’s ventricles, leading to enlarged ventricles without significantly elevated intracranial pressure. It classically presents with the triad of gait instability, urinary incontinence, and cognitive decline.

How is NPH treated?

The primary treatment is surgical implantation of a ventriculoperitoneal shunt, which diverts excess cerebrospinal fluid from the brain to the abdominal cavity for absorption. Many patients experience noticeable improvement in symptoms within days to weeks after the procedure.

Why do some patients not improve after shunt surgery?

Response to shunting varies based on the duration and severity of ventricular enlargement, the extent of irreversible brain tissue damage, and individual differences in cerebrospinal fluid dynamics. Preoperative biomarkers like the EOD index aim to identify those with the greatest potential for recovery.

Is the EOD index available for clinical employ now?

While the EOD index shows promise, it is currently primarily a research tool. Efforts are underway to refine and automate its calculation for broader clinical adoption, but widespread use may still be several years away pending further validation.

Can MRI alone diagnose NPH?

MRI is a key diagnostic tool for NPH, revealing characteristic ventricular enlargement. However, diagnosis requires a combination of clinical symptoms, imaging findings, and sometimes additional tests like lumbar drainage or cerebrospinal fluid tap trials to assess responsiveness to fluid removal.

As imaging technology and analytical methods advance, tools like the EOD index are helping bridge the gap between detection and personalized treatment—offering hope for more accurate prognoses and better outcomes in one of dementia’s most treatable forms.